



 **1-3 September 2025**  
 **Egypt International Exhibition Center**

## Regulatory Pathways for Pharma in Africa & MENA

As Africa and the MENA region emerge as critical growth markets for the pharmaceutical industry, regulatory clarity has become essential for manufacturers aiming to enter or expand in these regions. With varying frameworks, timelines, and technical requirements, choosing the right regulatory pathway can determine how quickly and efficiently your product reaches patients.

This guide outlines the key differences in the approval routes for **drug manufacturers**, **medical device makers**, and **API suppliers**, while highlighting opportunities in the West Africa pharma market and ongoing efforts toward gender parity in healthcare access.



### Understanding the Regulatory Landscape

Pharmaceutical manufacturers aiming to enter African and MENA markets face multiple regulatory routes depending on the product type, market entry strategy, and local authority requirements. Unlike the centralized systems in the U.S. or EU, many African nations operate independently, though regional harmonization is gaining momentum.

Here's how the primary pathways differ for regulatory approval:

#### 1. National Regulatory Authorities (NRAs)

Most countries in Africa and MENA have individual **National Regulatory Authorities** responsible for reviewing and approving drugs, biologics, APIs, and medical devices.

##### Key NRAs in the Region:

- **Egyptian Drug Authority (EDA)** – Egypt
- **National Agency for Food and Drug Administration and Control (NAFDAC)** – Nigeria
- **Moroccan Agency for Medicines and Health Products (DMP)** – Morocco
- **Saudi Food & Drug Authority (SFDA)** – Saudi Arabia





#### Steps for Approval:

- Submit Common Technical Document (CTD) format dossier
- Undergo quality, safety, and efficacy evaluations
- Comply with local pharmacovigilance and GMP inspection requirements
- Receive pricing and marketing approval

#### Pros:

- Tailored market entry strategies
- Growing opportunities for localization and partnerships

#### Challenges:

- Varying timelines and documentation standards
- Limited digital infrastructure in some markets



## 2. Regional Harmonization Initiatives

To reduce duplication and improve efficiency, many African countries are aligning regulatory processes through **regional harmonization programs**.


#### Key Initiatives:

- **WA-MRH:** West Africa Medicines Regulatory Harmonization under ECOWAS
- **ZAZIBONA:** Covers Southern African countries (e.g., Zambia, Zimbabwe, Namibia)
- **AMRH/AMA:** The African Medicines Agency (in progress) aims to create a pan-African regulatory framework

#### Benefits:

- Single submission reviewed by multiple countries
- Streamlined approvals for generics and essential medicines
- Supports local manufacturing and faster access to quality drugs

For manufacturers entering the West Africa pharma market, regional harmonization offers a practical route to scale market entry while minimizing redundant regulatory efforts.





### 3. International Approvals: FDA and EMA

Although focused on U.S. and European markets, many African countries recognize or fast-track products approved by:

- **FDA (U.S. Food and Drug Administration)**
- **EMA (European Medicines Agency)**
- **WHO Prequalification Program** for essential medicines

These approvals often serve as reference points or prerequisites for local approvals, especially for donor-funded health programs (e.g., HIV, malaria, maternal health).

This is particularly relevant to companies advancing solutions tied to gender parity in healthcare, including reproductive health, prenatal care, and access to essential women's medicines.



### 4. Fast-Track and Priority Review Programs

Some NRAs now offer **accelerated review pathways** for:

- Innovative therapies
- Essential generics in shortage
- Products addressing public health emergencies

Egypt's EDA and Nigeria's NAFDAC have piloted expedited reviews for high-impact products, reducing approval timelines from 12–18 months to as little as 6 months in some cases.


This is a strategic opportunity for companies offering:

- Vaccines and biologics
- Women's health products
- Chronic disease treatments

### Strategic Considerations for Manufacturers

When choosing your regulatory strategy in Africa and MENA, consider:

- **Target Market(s):** Focused national entry vs. multi-country expansion
- **Product Category:** New chemical entity, generic, biologic, or API
- **Reference Approvals:** FDA/EMA/WHO status to streamline submissions
- **Manufacturing Location:** Regional partnerships can strengthen local approval and distribution
- **Regulatory Capacity:** Some markets benefit from local consultants or agents familiar with national guidelines







## The Road Ahead: Regulatory Convergence & Inclusive Access

Africa's regulatory environment is evolving toward greater transparency, harmonization, and efficiency. At the same time, there's growing recognition of the need for inclusive healthcare policies, particularly around gender parity in healthcare, driving demand for approved, accessible pharmaceuticals that address the needs of women, children, and underserved populations.

## Join the Conversation at Pharmaconex 2025

Want to gain firsthand insight into regulatory best practices, harmonization efforts, and approval strategies in Africa and MENA?

**Pharmaconex 2025** is your gateway to:

- Meet regulators, consultants, and compliance experts
- Learn about drug registration requirements across African markets
- Explore trends shaping regional pharmaceutical investment and access

**Dates:** September 1 – 3, 2025

**Venue:** Egypt International Exhibition Center (EIEC), Cairo

**Register now:**

Don't miss this opportunity to position your company at the forefront of Africa's evolving pharmaceutical landscape.

